Pemetrexed + cisplatin: first-line for malignant pleural mesothelioma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1404, 2003-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed/cisplatin worth it in malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 593, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Raltitrexed + cisplatin beneficial for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1512, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 10, 2005-10 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines

By de Cupis A.   Semino C.   Pirani P.   Loprevite M.   Ardizzoni A.   Favoni R.E.  

European Journal of Pharmacology, Vol. 473, Iss. 2, 2003-07 ,pp. : 83-95

Elsevier

Access to resources Recommend Favorite